EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Regulatory news and changes

What should the clinic change in its next supplier agreement?

Dose Diligence research deskSection 04 · Page 15 of 17Last updated 17 Nov 2026

Negotiate around the ability to detect and manage a change—not a promise that regulation will remain unchanged. The following are analyst-recommended commercial protections, to be drafted by counsel:

Contract areaRequested protectionDecision owner
Product and facility identityNamed legal entities, physical sites, formulations and presentations; approval before substitutionProcurement + medical director
Regulatory eventsPrompt notice of relevant inspections, warnings, licence restrictions, recalls and loss of the stated supply basisCompliance
Evidence accessAccess to agreed quality, provenance and legal-basis documentation; process for resolving missing evidenceProcurement + counsel
CommitmentsSuspension/termination rights and treatment of deposits when the agreed route becomes unavailableCFO + counsel
Patient continuityResponsibilities for pending prescriptions, unshipped orders, refunds, records and communicationsCOO + clinical lead
Clinical informationOwnership of label updates, dosing-device instructions and safety escalationMedical director
Privacy and billingApproved data uses, subprocessors, charging triggers and cancellation supportSecurity + compliance

What is the recommended 30-day implementation plan?

These are management targets, not regulatory deadlines.

  1. Days 1–5 — map exposure. Identify every product, physical supplier site, destination state, commercial commitment and patient-facing programme. Separate clinic-owned stock from patient dispensing and facilitated branded access.
  2. Days 6–15 — close critical evidence gaps. Prioritise shortage-dependent claims, 503A personalisation workflows, 503B starting-material assumptions, vial-discard instructions and marketing claims. Hold new commitments where material eligibility evidence remains unresolved.
  3. Days 16–30 — test alternatives and exit mechanics. Complete a controlled fulfilment test, verify pharmacy coverage for selected states, test Bridge routing where relevant, and reconcile outstanding orders. Clinical leaders should direct any treatment transition; a purchasing review is not an instruction to interrupt treatment.

For the CFO, compare cost per successfully fulfilled patient-month, explicitly defined as fulfilment rather than clinical success. Report medicine, dispensing, shipping, wastage and internal handling separately, and identify whether each charge is paid by the clinic, patient or insurer.

Explore the table row by row

A working view of the research

Product and facility identity

Requested protection
Named legal entities, physical sites, formulations and presentations; approval before substitution
Decision owner
Procurement + medical director

Sources cited on this page

    See the section’s source register for the research context.

    Section sources →